ReP USP - Resultado da busca

Artigo de periodico
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial (2004)
Lemos, James A.; Blazing, Michael A.; Wiviott, Stephen D.; Lewis, Eldrin F.; Fox, Keith A. A.; White, Harvey D.; Rouleau, Jean-Lucien; Pedersen, Terje; Gardner, Laura H.; Mukherjee, Robin; Ramsey, Karen E.; Palmisano, Joanne; Bilheimer, David W.; Pfeffer, Marc A.; Califf, Robert M.; Braunwald, Eugene; Marin-Neto, José Antônio
Source: JAMA. Unidade: FMRP
Assunto: CORONARIOPATIA (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEMOS, James A. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA, v. 292, n. 11, p. 1307-1316, 2004Tradução . . Acesso em: 04 nov. 2024.
APA
Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., et al. (2004). Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA, 292( 11), 1307-1316.
NLM
Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen T, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Marin-Neto JA. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004 ; 292( 11): 1307-1316.[citado 2024 nov. 04 ]
Vancouver
Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen T, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Marin-Neto JA. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004 ; 292( 11): 1307-1316.[citado 2024 nov. 04 ]
Trabalho de evento-resumo periodico
Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study (2004)
Sampson, Uchechukwu K.; Kenchaiah, Satish; Swedberg, k.; White, Harvey; Lokhnygina, Yuliya; Mareev, Viacheslav; Barvik, Stale; Francis, Gary S.; Marin Neto, José Antônio; Werf, Frans Van de; Rouleau, Jean-Lucien; Pfeffer, Marc A.; Solomon, Scott
Source: Circulation. Conference titles: Scientific Sessions. Unidade: FMRP
Assunto: INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SAMPSON, Uchechukwu K. et al. Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study. Circulation. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 04 nov. 2024. , 2004
APA
Sampson, U. K., Kenchaiah, S., Swedberg, k., White, H., Lokhnygina, Y., Mareev, V., et al. (2004). Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study. Circulation. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
NLM
Sampson UK, Kenchaiah S, Swedberg k., White H, Lokhnygina Y, Mareev V, Barvik S, Francis GS, Marin Neto JA, Werf FV de, Rouleau J-L, Pfeffer MA, Solomon S. Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study. Circulation. 2004 ; 110( 17): III-642.[citado 2024 nov. 04 ]
Vancouver
Sampson UK, Kenchaiah S, Swedberg k., White H, Lokhnygina Y, Mareev V, Barvik S, Francis GS, Marin Neto JA, Werf FV de, Rouleau J-L, Pfeffer MA, Solomon S. Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study. Circulation. 2004 ; 110( 17): III-642.[citado 2024 nov. 04 ]
Artigo de periodico
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (2003)
Pfeffer, Marc A.; McMurray, John J. V.; Velazquez, Eric J.; Rouleau, Jean-Lucien; Kober, Lars; Maggioni, Aldo P.; Solomon, Scott D.; Swedberg, Karl; Van de Werf, Frans; White, Harvey; Leimberger, Jeffrey D.; Henis, Marc; Edwards, Susan; Zelenkofske, Steven; Sellers, Mary Ann; Califf, Robert M.; Marin-Neto, José Antônio
Source: New England Journal of Medicine. Unidade: FMRP
Subjects: FÁRMACOS (SISTEMA CARDIOVASCULAR), INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PFEFFER, Marc A. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, v. 349, p. 1893-1906, 2003Tradução . . Disponível em: https://doi.org/10.1016/j.accreview.2003.12.039. Acesso em: 04 nov. 2024.
APA
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J. -L., Kober, L., Maggioni, A. P., et al. (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, 349, 1893-1906. doi:10.1016/j.accreview.2003.12.039
NLM
Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Marin-Neto JA. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [Internet]. New England Journal of Medicine. 2003 ; 349 1893-1906.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1016/j.accreview.2003.12.039
Vancouver
Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Marin-Neto JA. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [Internet]. New England Journal of Medicine. 2003 ; 349 1893-1906.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1016/j.accreview.2003.12.039
Artigo de periodico
Comparison of omapatrilat and enalapril in patients with chronic heart failure (2002)
Packer, Milton; Califf, Robert M.; Konstam, Marvin A.; Krum, Henry; McMurray, John J.; Rouleau, Jean-Lucien; Swedberg, Karl; Marin-Neto, José Antônio
Source: Circulation. Unidade: FMRP
Assunto: CARDIOPATIAS (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PACKER, Milton et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation, v. 103, p. 920-926, 2002Tradução . . Acesso em: 04 nov. 2024.
APA
Packer, M., Califf, R. M., Konstam, M. A., Krum, H., McMurray, J. J., Rouleau, J. -L., et al. (2002). Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation, 103, 920-926.
NLM
Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J-L, Swedberg K, Marin-Neto JA. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation. 2002 ; 103 920-926.[citado 2024 nov. 04 ]
Vancouver
Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J-L, Swedberg K, Marin-Neto JA. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation. 2002 ; 103 920-926.[citado 2024 nov. 04 ]
Artigo de periodico
Valsartan in acute myocardial infarction trial (valiant): rationale and design (2000)
Pfeffer, Marc A.; McMurray, John; Leizorovicz, Alain; Maggioni, Aldo P.; Rouleau, Jean-Lucien; Van de Werf, Frans; Henis, Marc; Neuhart, Eric; Gallo, Paul; Edwards, Susan; Sellers, Mary Ann; Velazquez, Eric; Califf, Robert; Marin-Neto, José Antônio (Organizador)
Source: American Heart Journal. Unidade: FMRP
Subjects: DOENÇAS CARDIOVASCULARES (EPIDEMIOLOGIA), CARDIOPATIAS, FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PFEFFER, Marc A. et al. Valsartan in acute myocardial infarction trial (valiant): rationale and design. American Heart Journal, v. 140, n. 5, p. 727-734, 2000Tradução . . Acesso em: 04 nov. 2024.
APA
Pfeffer, M. A., McMurray, J., Leizorovicz, A., Maggioni, A. P., Rouleau, J. -L., Van de Werf, F., et al. (2000). Valsartan in acute myocardial infarction trial (valiant): rationale and design. American Heart Journal, 140( 5), 727-734.
NLM
Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau J-L, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (valiant): rationale and design. American Heart Journal. 2000 ; 140( 5): 727-734.[citado 2024 nov. 04 ]
Vancouver
Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau J-L, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (valiant): rationale and design. American Heart Journal. 2000 ; 140( 5): 727-734.[citado 2024 nov. 04 ]

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em

Non normalized affiliation